Publications

Following is a list of our selected publications. You can click on the name of the paper to be taken directly to the PubMed link for the paper. To see the full list, please click here. Additionally, to read about recent news highlighting our work, please click here.

Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. PMID: 38653864; PMCID: PMC11108776.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Weigelt B, Zamarin D. Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity. bioRxiv. 2023 Aug 11:2023.08.08.552544.

Duska LR, Zamarin D, Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher EM. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023 Sep;7:e2300235

Lam C, Sarasohn D, Weigelt B, Zamarin D. Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer. Gynecol Oncol Rep. 2023 Aug 11;49:101258.

Khushalani NI, Harrington KJ, Melcher A, Bommareddy PK, Zamarin D. Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment. Mol Ther Oncolytics. 2023 Sep 19;31:100729\

Henson CE, Morton DJ, Mayadev JS, Wong SJ, Zamarin D. Cancer trials as opportunities to serve and learn from individuals with human immunodeficiency virus. Cancer. 2023 Mar 1;129(5):664-667.

Dessources K, Ferrando L, Zhou QC, Iasonos A, Abu-Rustum NR, Reis-Filho JS, Riaz N, Zamarin D*, Weigelt B*. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. Gynecol Oncol. 2023 Apr;171:15-22. *equal contribution

Liu YL, Zamarin D. Shedding light on PARP inhibitor response through functional imaging. Clin Cancer Res. 2023 Apr 14;29(8):1384-1386.

Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. Gynecol Oncol. 2023 Feb;169:64-69.

Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D*, Shah SP*. Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022 Dec;612(7941):778-786. *equal contribution

Funnell T, O'Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium, Shah SP, Aparicio S. Single-cell genomic variation induced by mutational processes in cancer. Nature. 2022 Oct 26. doi: 10.1038/s41586-022-05249-0. Online ahead of print.

Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, Holm JS, Rosenberg JE, Shah SP, Vázquez-García I, Weigelt B, Wu M, Zamarin D, Campitelli LF, Osborne EJ, Klinger M, Robins HS, Khincha PP, Savage SA, Balachandran VP, Wolchok JD, Hellmann MD, Merghoub T, Levine AJ, Łuksza M, Greenbaum BD. Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Jun;606(7912):172-179.

Boehm KM, Aherne EA, Ellenson L, Nikolovski I, Alghamdi M, Vázquez-García I, Zamarin D, Roche KL, Liu Y, Patel D, Aukerman A, Pasha A, Rose D, Selenica P, Causa Andrieu PI, Fong C, Capanu M, Reis-Filho JS, Vanguri R, Veeraraghavan H, Gangai N, Sosa R, Leung S, McPherson A, Gao J; MSK MIND Consortium, Lakhman Y, Shah SP. Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nat Cancer. 2022 Jun;3(6):723-733

Ma X, Riaz N, Samstein RM, Lee M, Makarov V, Valero C, Chowell D, Kuo F, Hoen D, Fitzgerald CWR, Jiang H, Alektiar J, Alban TJ, Juric I, Parthasarathy PB, Zhao Y, Sabio EY, Verma R, Srivastava RM, Vuong L, Yang W, Zhang X, Wang J, Chu LK, Wang SL, Kelly DW, Pei X, Chen J, Yaeger R, Zamarin D, Zehir A, Gönen M, Morris LGT, Chan TA. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat Genet. 2022 Jul;54(7):996-1012

Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. Int J Gynecol Cancer. 2022; 8:1017.

Osorio JC, Zamarin D. Beyond T cells: IgA incites immune recognition in endometrial cancer. Cancer Res. 2022 Mar 1;82(5):766-768

Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, Casado J, Kossenkov AV, Song M, Barrat FJ, Holcomb K, Romero-Sandoval EA, Zamarin D, Pepin D, D'Andrea AD, Farkkila A, Cubillos-Ruiz JR. Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer. Cancer Discov. 2022 Aug 5;12(8):1904-1921.

Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, Swisher EM, Kohn EC, Zamarin D. State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. JCO Precis Oncol. 2022 Oct;6:e2200355. doi: 10.1200/PO.22.00355.

Uhlitz F, Zamarin D. Rejuvenating dysfunctional T cells in ovarian cancer: CD28 is the license to kill. Cancer Cell. 2021 Dec 13;39(12):1567-1569.

Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discov. 2021; 11(8):1896-1912

Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T. Tim-4⁺ cavity-resident macrophages impair anti-tumor CD8⁺ T cell immunity. Cancer Cell. 2021 Jul 12;39(7):973-988

Friedman CF, Snyder A, de Meritens AB, Cantrell L, Corr B, Fu S, Konner J, Konstatinopoulos P, Iasonos A, Aghajanian C, Zamarin D. A Phase 2 Study of Atezolizumab in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. J. Immunother. Cancer (2020). e001126.

Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall M, Hong D. Regulatory T cell depletion with Mogamulizumab in Combination with the Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: a Phase I Study. Clin. Canc. Res. 26(17):4531-4541 (2020).

Zamarin D, O’Cearbhaill RE, Holland A, Walderich S, Cadoo KA, Gallagher J, Kravetz S, Mcdonnell A, Troso-Sandoval T, Sabbatini P, Lichtman S, Tew W, Makker V, Grisham RN, Hyman DM, Erskine C, Block MS, Knutson KL, Aghajanian C, Konner JA. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. J. Immunother. Cancer 2020. Jun;8(1):e000829 Epub ahead of print.

Boland JL, Zhou Q, Iasonos AE, O’Cearbhaill R, Konner J, Callahan M, Friedman C, Aghajanian C, Sabbatini P, Zamarin D^*, Cadoo KA^* Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecol Oncol. 152(2):251-258 (2020).*equal contribution

Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M., Feit ZH, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ, Friedman C, Cadoo K, Grisham R, Konner JA, O’Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, Zamarin D. BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. JCO Prec. Oncol 2020 Jun 16;4:PO.20.00069. Epub ahead of print.

Zamarin D, Burger RA, Sill MW, Powell DJ, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. A Randomized Phase II Trial Of Nivolumab Vs. Nivolumab And Ipilimumab For Recurrent Or Persistent Ovarian Cancer: An NRG Oncology Study. J. Clin Oncol. 38:1814 (2020).

Bykov Y, Kim SH, Zamarin D. Preparation of single cells from tumors for single-cell RNA sequencing. Methods in Enzymology. 2020; 632: 295-308

Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecol Oncol. 2019 Oct;155(1):51-57

Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara SJ, Zamarin D, Walther T, Snyder AC, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman M, Kaye J, Betel D, Philip M, Schietinger A. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019 Jul;571(7764):270-274

Vijayakumar G, Zamarin D. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. Methods in Molecular Biology. 2020; 2058:133-154.

Burman B, Pesci G, Zamarin D. Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers (Basel). 2020 Nov 28;12(12):E3552.

Zamarin D. Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum? Mol. Ther 6;27(11):1874-1877 (2019).

Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D. Immune-active microenvironment in SCCOHT: rationale for therapy with immune checkpoint blockade. J. Natl. Cancer Inst. 2018; Jul 1;110(7):787-790.

Zamarin D., Ricca J.M., Sadekova S., Oseledchyk A., Yu Y., Blumenschein W.M., Wong J., Gigoux M., Merghoub T., Wolchok J.D. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J. Clin. Invest. 2018 Apr 2;128(4):1413-1428

Ricca J., Oseledchyk A., Walther T., Liu C., Mangarin L., Merghoub T., Wolchok J.D., Zamarin D. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol. Ther. 2018 Apr 4;26(4):1008-1019

Oseledchyk A., Gennarelli R.L., Leitao M.M., Aghajanian C.A., Iasonos A., Zivanovic O., Zamarin D. Adjuvant Chemotherapy in Patients with Operable Granulosa Cell Tumors of the Ovary: A Surveillance, Epidemiology, and End Results Cohort Study. Cancer Medicine. 2018 Jun;7(6):2280-2287

Oseledchyk A., Ricca J.M., Gigoux M., Ko B., Redelman-Sidi G., Walther T., Liu C., Iyer G., Merghoub T., Wolchok J.D., Zamarin D. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 2018 Jun 19;9(47):28702-28716

Bykov Y, Zamarin D. Virus, vessel, victory: a novel approach to tumor killing. Clin Cancer Res. 2018

Ricca J., Oseledchyk A., Zamarin D. Locoregional therapeutics: using one’s own tumor as a vaccine. Targeted Oncology. 19:172-181 (2017).

Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, Sala E, Merghoub T, Snyder A, Miller ML. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell 2017; 170: 927-938.

Zamarin D., Holmgaard R.B., Ricca J., Plitt T., Palese P., Sharma P., Merghoub T., Wolchok J.D., Allison J.P. Intratumoral modulation of the inducible costimulator (ICOS) by recombinant oncolytic virus promotes systemic anti-tumor immunity. Nat Commun 2017; 8:14340.

Holmgaard R.B., Zamarin D., Lesokhin A., Merghoub T., Wolchok J.D. CSF-1 receptor blockade overcomes resistance to immunomodulatory antibody and IDO-based immunotherapy in MDSC-driven tumors. Ebiomedicine 2016; 6:50-8.

Zamarin D. and Jazaeri A.A. Leveraging Immunotherapy for the treatment of Gynecologic Cancers in the Era of Precision Medicine. Gynecologic Oncology. 141:86-94 (2016).

Holmgaard R.B., Zamarin D., Li Y., Gasmi B., Munn D.H., Allison J.P., Merghoub T., Wolchok J.D. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Reports. 2015;13:412-24.

Zamarin D., Holmgaard R.B., Subudhi S.K., Park J., Mansour M., Palese P., Merghoub T., Wolchok J.D., and Allison J.P. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med.2014; 6:226ra32.

Holmgaard R.B., Zamarin D., Munn D.H., Wolchok J.D., and Allison J.P. Indoleamine 2,3-dioxygenase is a critical mechanism of resistance for anti-tumor T-cell immunotherapies targeting immune checkpoints. J. Exp. Med. 2013; 210:1389-402.